全文获取类型
收费全文 | 221168篇 |
免费 | 4775篇 |
国内免费 | 116篇 |
专业分类
耳鼻咽喉 | 1517篇 |
儿科学 | 8454篇 |
妇产科学 | 4334篇 |
基础医学 | 23097篇 |
口腔科学 | 2512篇 |
临床医学 | 18765篇 |
内科学 | 39592篇 |
皮肤病学 | 1579篇 |
神经病学 | 21047篇 |
特种医学 | 10025篇 |
外科学 | 32776篇 |
综合类 | 2770篇 |
一般理论 | 62篇 |
预防医学 | 23557篇 |
眼科学 | 3381篇 |
药学 | 12092篇 |
2篇 | |
中国医学 | 677篇 |
肿瘤学 | 19820篇 |
出版年
2024年 | 61篇 |
2023年 | 431篇 |
2022年 | 603篇 |
2021年 | 1291篇 |
2020年 | 958篇 |
2019年 | 1425篇 |
2018年 | 23233篇 |
2017年 | 18392篇 |
2016年 | 20670篇 |
2015年 | 2296篇 |
2014年 | 2572篇 |
2013年 | 3375篇 |
2012年 | 10566篇 |
2011年 | 24577篇 |
2010年 | 20710篇 |
2009年 | 13273篇 |
2008年 | 22385篇 |
2007年 | 24644篇 |
2006年 | 3608篇 |
2005年 | 5017篇 |
2004年 | 6132篇 |
2003年 | 6859篇 |
2002年 | 4780篇 |
2001年 | 657篇 |
2000年 | 708篇 |
1999年 | 502篇 |
1998年 | 737篇 |
1997年 | 595篇 |
1996年 | 446篇 |
1995年 | 444篇 |
1994年 | 370篇 |
1993年 | 329篇 |
1992年 | 243篇 |
1991年 | 258篇 |
1990年 | 287篇 |
1989年 | 207篇 |
1988年 | 188篇 |
1987年 | 145篇 |
1986年 | 144篇 |
1985年 | 143篇 |
1984年 | 127篇 |
1983年 | 126篇 |
1982年 | 156篇 |
1981年 | 126篇 |
1980年 | 144篇 |
1979年 | 71篇 |
1978年 | 77篇 |
1974年 | 60篇 |
1938年 | 64篇 |
1932年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
33.
Skoug John W. Borin Marie T. Fleishaker Joseph C. Cooper Anne M. 《Pharmaceutical research》1991,8(12):1482-1488
The mechanism of release from sustained-release adinazolam mesylate tablets was assessed by the Higuchi equation and by analysis of drug release profiles through 60% released using the Peppas equation. Computed values of the diffusional exponent, n, ranged from 0.59 to 0.66. Values of n in this range are consistent with a mixed mechanism of release, with diffusion of drug through the hydrated polymer matrix and relaxation of this matrix being the principal processes controlling release. The rate of in vitro drug release was increased for half tablets relative to whole tablets and is attributed to an increase in the surface to volume ratio of half tablets of about 16%. This increase in surface-to-volume ratio of half tablets was reflected by an increase in the constant, k, from the Peppas equation of 20–23% and by an increase in the slope of Higuchi plots of 12–18% for four lots of tablets. In vivo/in vitro relationships from two bioavailability studies were thoroughly evaluated. Using either a linear or a quadratic relationship, an in vivo/in vitro correlation exists for sustained-release adinazolam mesylate tablets. 相似文献
34.
35.
36.
Henry Cisneros 《AIDS and behavior》2007,11(2):7-8
For persons battling HIV/AIDS a stable place to live may decide the length and quality of life itself. It is nearly impossible for a person on the streets to engage in a needed continuous AIDS treatment regimen when the very basic question of where that person will rest his or her head when darkness comes in just a few hours is unresolved. When danger lurks on the streets, when cold numbs the limbs, when tiredness overwhelms the mind, when fear breaks the spirit, a place to call home would make all the difference. 相似文献
37.
38.
Background
Reports on childhood cancer survivors estimated cumulative probability of developing secondary neoplasms vary from 3,3% to 25% at 25 years from diagnosis, and the risk of developing another cancer to several times greater than in the general population. 相似文献39.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
40.